Intellectual Property India Publishes Patent Application for 'Anti-EGFRVIII Antibodies And Uses Thereof' Filed by Phanes Therapeutics, Inc.

MUMBAI, India, June 6 -- Intellectual Property India has published a patent application (202517048063 A) filed by Phanes Therapeutics, Inc., San Diego, on May 19, for 'anti-egfrviii antibodies and uses thereof.'

Inventor(s) include Wu, Huiwen; Jia, Haiqun; and Zou, Hui.

The application for the patent was published on June 6, under issue no. 23/2025.

According to the abstract released by the Intellectual Property India: "Anti-EGFRvIII antibodies and antigen-binding fragments thereof and chimeric antigen receptors (CARs) comprising anti-EGFRvIII antigen-binding domains are described. Also described are nucleic acids encoding the antibodies and CARs, compositions comprising the antibodies and host cells comprising the CARs, methods of producing the antibodies and CARs, and methods of using the antibodies and CARs for treating or preventing diseases such as cancer and/or an inflammatory" disease, and/or autoimmune disease."

The patent application was internationally filed on Oct. 23, 2023, under International application No.PCT/US2023/077521.

Disclaimer: Curated by HT Syndication.